Page 62 - 2023 Taiwan Food and Drug Administration Annual Report
P. 62
2023 Taiwan Food and
Drug Administration
Annual Report
Figure 4-1 Solution production line equipment ▍ Achievements and Benefits
chart - filling equipment
In 2022, the Factory completed the
Figure 4-2 Solution production line equipment production line for solutions and obtained
chart - packaging equipment permits for Methadone Oral Concentrate and
Morphine Sulfate Oral Solution. Approval for
▍ Implementation Strategy the manufacturing and self-mass production of
solutions was also received and research and
The plan is to add production lines for development of Oxycodone Hydrochloride
new formulations in the newly renovated Immediate Release Capsules, Morphine
workshops. The goal is to build production Sulfate Prolonged Release Capsules, and
lines for solutions, capsules, and patches Matrix Patches are ongoing. The Factory's
and maximize space for production and future product range will include injections,
warehousing each year. Injections and tablets, solutions, capsules, and patches, with
solutions are given priority for R&D products, a self-production rate of up to 70%. The filling
followed by capsules and patches, which equipment and packaging equipment for the
require more advanced technology. solution line are shown in Figures 4-1 and 4-2.
Section 3
Enhance Drug
Abuse Early Warning
Mechanism
▍ Introduction of the Policy
New psychoactive substances (NPSs)
have a wide range of varieties and have
developed rapidly. In order to effectively
monitor NPSs, TFDA continues to reinforce
the capacity of domestic accredited institutions
60
